Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):749-55. doi: 10.1007/s00259-007-0691-z.

2.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
3.

Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.

Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP.

Hematol Oncol Clin North Am. 2007 Jun;21(3):561-73; x. Review.

PMID:
17548040
4.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP.

Semin Nucl Med. 2010 Mar;40(2):78-88. doi: 10.1053/j.semnuclmed.2009.10.004. Review.

PMID:
20113677
5.

Peptide-receptor radionuclide therapy for endocrine tumors.

van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ.

Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Review.

PMID:
19488074
6.

Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP.

Q J Nucl Med Mol Imaging. 2006 Dec;50(4):265-71. Review.

7.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12. doi: 10.1007/s00259-011-2039-y. Review.

8.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. Review.

9.

Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.

Nisa L, Savelli G, Giubbini R.

Ann Nucl Med. 2011 Feb;25(2):75-85. doi: 10.1007/s12149-010-0444-0. Review.

PMID:
21107762
10.

[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Halperin DM, Dasari A, Yao JC.

Future Oncol. 2016 Feb;12(3):313-21. doi: 10.2217/fon.15.321. Review.

PMID:
26759064
11.

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G.

Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. Review.

PMID:
15150675
12.

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW.

Endocr Relat Cancer. 2003 Dec;10(4):451-8. Review.

13.

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.

Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Review.

14.

[New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].

Rubello D, Rufini V, De Carlo E, Martini C, Calcagni ML, Sicolo N, Troncone L, Casara D.

Minerva Endocrinol. 2003 Dec;28(4):259-96. Review. Italian.

PMID:
14752399
15.

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.

van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ.

Neuroendocrinology. 2013;97(1):74-85. doi: 10.1159/000335018. Review.

PMID:
22237390
16.
17.

Neuroendocrine tumors. Peptide receptor radionuclide therapy.

Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP.

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29. Review.

PMID:
17382268
18.

[Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].

Simonenko VB, Dulin PA, Makanin MA.

Klin Med (Mosk). 2006;84(4):4-8. Review. Russian.

PMID:
16755846
19.

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP.

Semin Nucl Med. 2016 May;46(3):225-38. doi: 10.1053/j.semnuclmed.2015.12.003. Review.

PMID:
27067503
20.

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G.

Thorac Surg Clin. 2014 Aug;24(3):333-49. doi: 10.1016/j.thorsurg.2014.04.005. Review. Erratum in: Thorac Surg Clin. 2014 Nov;24(4):xv.

PMID:
25065935
Items per page

Supplemental Content

Support Center